MX2017005814A - Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion. - Google Patents
Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion.Info
- Publication number
- MX2017005814A MX2017005814A MX2017005814A MX2017005814A MX2017005814A MX 2017005814 A MX2017005814 A MX 2017005814A MX 2017005814 A MX2017005814 A MX 2017005814A MX 2017005814 A MX2017005814 A MX 2017005814A MX 2017005814 A MX2017005814 A MX 2017005814A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- production
- dimeric immunoglobulins
- hetero
- cell retargeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a inmunoglobulinas hetero-diméricas que dirigen un componente del antígeno CD3 humano y un componente del antígeno CD38 humano y a métodos para fabricar el mismo; la presente invención también se refiere a anticuerpos que se unen al antígeno CD38 humano y sus derivados para usarse como reactivos terapéuticos o de diagnóstico y métodos para fabricarlos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2014/073738 WO2015063339A1 (en) | 2013-11-04 | 2014-11-04 | Production of t cell retargeting hetero-dimeric immunoglobulins |
EP15167034 | 2015-05-08 | ||
PCT/EP2015/075628 WO2016071355A1 (en) | 2014-11-04 | 2015-11-03 | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017005814A true MX2017005814A (es) | 2017-08-02 |
Family
ID=53059011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017005814A MX2017005814A (es) | 2014-11-04 | 2015-11-03 | Inmunoglobulinas hetero-dimericas de redireccionamiento de celulas t cd3/cd38 y sus metodos de produccion. |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP3215541A1 (es) |
JP (3) | JP2018501297A (es) |
KR (1) | KR20170078831A (es) |
CN (1) | CN107207596A (es) |
AU (1) | AU2015341884B2 (es) |
BR (1) | BR112017009263A2 (es) |
CA (1) | CA2965745C (es) |
CL (1) | CL2017001090A1 (es) |
CO (1) | CO2017005240A2 (es) |
EA (1) | EA039658B1 (es) |
HK (1) | HK1244014A1 (es) |
IL (1) | IL251848A0 (es) |
MA (1) | MA40894A (es) |
MX (1) | MX2017005814A (es) |
MY (1) | MY186929A (es) |
NZ (1) | NZ732019A (es) |
PE (1) | PE20171041A1 (es) |
PH (1) | PH12017500819A1 (es) |
SG (1) | SG11201703313SA (es) |
WO (1) | WO2016071355A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
WO2015013671A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
SG11201603244VA (en) | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
ME03666B (me) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecifična antitela koja se vezuju za cd38 i cd3 |
EP3172235A2 (en) * | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
KR20170084326A (ko) | 2014-11-26 | 2017-07-19 | 젠코어 인코포레이티드 | Cd3 및 종양 항원과 결합하는 이종이량체 항체 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
EP4257613A3 (en) | 2016-06-14 | 2023-12-13 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
CN110831968A (zh) * | 2017-04-24 | 2020-02-21 | 伊克诺斯科学公司 | 用于治疗egfr阳性癌症的t细胞重定向双特异性抗体 |
WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
KR102651965B1 (ko) | 2017-06-05 | 2024-03-28 | 누맙 세러퓨틱스 아게 | 신규 항 cd3 항체 |
EP3635001A1 (en) | 2017-06-08 | 2020-04-15 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
KR20200021068A (ko) * | 2017-06-08 | 2020-02-27 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
TW201910349A (zh) | 2017-08-10 | 2019-03-16 | 美商格里佛診斷方法股份有限公司 | 包含重組人類cd38細胞外區域之組合物、方法及/或套組 |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
JP7299873B2 (ja) | 2017-08-16 | 2023-06-28 | ブラック ベルト セラピューティクス リミテッド | Cd38抗体 |
US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
TW201927816A (zh) | 2017-10-14 | 2019-07-16 | 美商Cytomx生物製藥公司 | 抗體、可活化之抗體、雙特異性抗體、和雙特異性可活化之抗體、及其使用方法 |
AU2019348606A1 (en) * | 2018-09-25 | 2021-04-15 | Ichnos Sciences S.A. | Antibody quantification in biological samples |
KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
CN113614107A (zh) * | 2019-01-23 | 2021-11-05 | Encefa公司 | Cd31竞争剂及其用途 |
US20220177582A1 (en) * | 2019-03-13 | 2022-06-09 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
CN113874399A (zh) * | 2019-05-23 | 2021-12-31 | 维洛斯生物股份有限公司 | 抗ror1/抗cd3双特异性结合分子 |
US20220227887A1 (en) * | 2019-06-11 | 2022-07-21 | Ono Pharmaceutical Co., Ltd. | Immunosuppressant |
CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
CA3152438A1 (en) * | 2019-09-30 | 2021-04-08 | Harbour Biomed (suzhou) Co., Ltd. | Cd3-targeting antibody, bispecific antibody and use thereof |
CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
JP2023523584A (ja) * | 2020-04-24 | 2023-06-06 | メモリアル スローン ケタリング キャンサー センター | 抗cd3抗体及びその使用 |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
JP2023530675A (ja) * | 2020-06-17 | 2023-07-19 | ワイ-マブス セラピューティクス, インコーポレイテッド | ヒト疾患の治療のためのcd38抗体 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1720907T3 (en) * | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies as well as applications therefor |
CN112480257A (zh) * | 2005-03-23 | 2021-03-12 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
RS56677B1 (sr) * | 2005-10-12 | 2018-03-30 | Morphosys Ag | Proizvodnja i karakterizacija potpuno humanih terapeutskih antitela dobijenih hucal gold tehnologijom, specifičnih za humani cd38 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP2445936A1 (en) * | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
MX2012007497A (es) * | 2009-12-25 | 2012-08-01 | Chugai Pharmaceutical Co Ltd | Metodo para modificacion de polipeptidos para purificar multimeros de polipeptido. |
WO2011154453A1 (en) * | 2010-06-09 | 2011-12-15 | Genmab A/S | Antibodies against human cd38 |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
BR112013023918A2 (pt) * | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
IN2015MN00139A (es) * | 2012-09-25 | 2015-10-16 | Glenmark Pharmaceuticals Sa | |
DK2914302T3 (en) * | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
SG11201603244VA (en) * | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 KR KR1020177015252A patent/KR20170078831A/ko not_active Application Discontinuation
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/en not_active Withdrawn
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/en active Application Filing
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 CA CA2965745A patent/CA2965745C/en active Active
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
-
2018
- 2018-03-12 HK HK18103440.0A patent/HK1244014A1/zh unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR20170078831A (ko) | 2017-07-07 |
MA40894A (fr) | 2017-09-12 |
WO2016071355A1 (en) | 2016-05-12 |
IL251848A0 (en) | 2017-06-29 |
CN107207596A (zh) | 2017-09-26 |
MY186929A (en) | 2021-08-26 |
PE20171041A1 (es) | 2017-07-19 |
JP2018501297A (ja) | 2018-01-18 |
HK1244014A1 (zh) | 2018-07-27 |
CA2965745C (en) | 2023-12-05 |
AU2015341884B2 (en) | 2020-09-17 |
CL2017001090A1 (es) | 2018-01-05 |
CO2017005240A2 (es) | 2017-10-31 |
NZ732019A (en) | 2022-07-29 |
SG11201703313SA (en) | 2017-05-30 |
JP2019214582A (ja) | 2019-12-19 |
CA2965745A1 (en) | 2016-05-12 |
JP7403505B2 (ja) | 2023-12-22 |
AU2015341884A1 (en) | 2017-06-08 |
PH12017500819A1 (en) | 2017-10-02 |
JP2021184722A (ja) | 2021-12-09 |
EA201790961A1 (ru) | 2017-10-31 |
EA039658B1 (ru) | 2022-02-22 |
EP3215541A1 (en) | 2017-09-13 |
BR112017009263A2 (pt) | 2018-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500819A1 (en) | Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production | |
MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
PH12017502019A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
MX2021003704A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
PH12016501908A1 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
GEP20227343B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
MX2016009050A (es) | Construcciones biespecificas de union a los antigenos cd3 y cd19. | |
MX2016016883A (es) | Anticuerpo anti-axl. | |
PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
MX2018003183A (es) | Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas. | |
NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
NZ724772A (en) | Antibodies against hpa-1a | |
MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. |